HuMax-IL8 (now known as BMS-986253) is a fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine with direct and indirect tumor-promoting effects, mediated by immune escape and the recruitment of myeloid-derived suppressor cells [54]. The gene discussed is CXCL8; the disease is neoplasm.